The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome

The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK’s population-based Haematological Malignancy Research Network

“…As with many other chronic diseases, hospital admissions for rheumatological disorders are comparatively rare. However, as detailed by the UK’s National Institute for Health and Clinical Care Excellence (NICE), the diagnosis and treatment of autoimmune/inflammatory conditions like rheumatoid arthritis and Sjögren’s Syndrome require specialist clinical input, and patients are diagnosed and managed as outpatients in secondary care [ 27 , 28 ]. Hence, for the purposes of the present analysis, data on all secondary care episodes in both inpatient and outpatient settings between April 2003 and the date of B-cell malignancy diagnosis (patient cohort members), or the corresponding pseudo-diagnosis date (comparator cohort members), were obtained for all individuals via linkage to HES.…”

In this together

“…1 I have no problem in agreeing with his assertions and interpretations of how our profession has got to be here. However, I' d like to add a few more perspectives to the debate.…”

Treatment of serologically negative Sjögren’s syndrome with tacrolimus: A case report

“…20 Moreover, according to the 2017 British Society for Rheumatology guidelines on the management of adult pSS, external tacrolimus can be used as a substitute for hydroxychloroquine in patients with discomfort. 21 Tacrolimus at 1 mg twice a day is frequently prescribed for subsequent immunoregulatory treatment. In the current case, the patient's dry mouth was significantly improved and her IgG level was normal after 3 months of treatment.…”